A NOVEL SOLUBLE BIOMARKER FOR INSULIN RESISTANCE

摘要

The present invention relates to a novel soluble biomarker for insulin resistance: 1-methyl nicotinamide (MNA). The invention relates to methods of determining the degree of insulin resistance in a patient. The invention further relates to methods for determining whether a subject with insulin resistance or type 2 diabetes will benefit from a treatment with an inhibitor of nicotinamide-N-methyltransferase (NNMT) or whether a subject responds to a therapeutic treatment with an NNMT inhibitor. The invention also relates to methods of adjusting the dose of an NNMT inhibitor applied for therapeutic treatment of insulin resistance or type-2 diabetes

主权项

1. A method of determining whether a patient with insulin resistance or type-2 diabetes (T2D) will benefit from a therapeutic treatment with an inhibitor of nicotinamide-N-methyltransferase (NNMT), said method comprising the steps:
determining the level of 1-methylnicotinamide (MNA) in a blood sample isolated from the patient; and comparing the level of MNA in the blood sample with a reference level of MNA;wherein an increased MNA level in the blood sample isolated from the patient as compared to the reference level of MNA indicates that the patient will benefit from said therapeutic treatment.